Pfizer says it’s moving forward with its Phase 2/3 trial in the pediatric population and expects to provide the COVID-19 vaccine to children between the ages of 5–11 in the fall, and soon after for those 4 and younger, if studies show immune response and safety. “If safety and immunogenicity is confirmed, and pending authorization or approval from regulators, we hope to submit the vaccine for potential Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) sometime in September-October timeframe for children 5–11, and soon after for 6 months to 5,” Pfizer stated. Pfizer developed its vaccine in partnership with BioNTech, a German biotechnology company. The pharmaceutical company is testing its vaccine at lower doses in three different age groups: 5 to 11 years, 2 to 5 years, and 6 months to 2 years, to examine vaccine efficacy, safety, and immunity. The vaccine’s effectiveness will be inferred …